SCHEMBL27260511

SCHEMBL27260511

N=[S@@](=O)(CC[C@@H](O)C(F)(F)F)CC[C@H](N)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.51
GSR P00390 2/20 0.39
GCLC P48506 1/20 0.38
CYP1A2 P05177 2/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
SLC1A1 P43005 1/20 0.37
GRIA4 P48058 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIK2 Q13002 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27259228 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25223050 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25233629 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL27259226 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25223053 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25266297 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25205657 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25233633 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL25233631 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8
SCHEMBL27257205 1.00 PMP22 (0.51) PMP22GSRGCLCCYP1A2GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
WO-2024030960-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS AIFM2, GPX4, HMOX1 PMP22 4845/4885GSR 33/4885GCLC 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.